Exosomes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the exosomes market size is expected to increase from USD 0.71 billion in 2025 to USD 0.89 billion in 2026 and reach USD 2.78 billion by 2031, growing at a CAGR of 25.55% over 2026-2031.

This report is Segmented by Product (Kits and Reagents, and More), Workflow (Isolation Methods [Ultracentrifugation, and More] and Downstream Analysis), Biomolecule Type (Proteins & Peptides, and More), Source (MSC-Derived, and More), Application (Diagnostics and Therapeutics), End-User (Hospitals & Clinics, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Exosomes Market Trends and Insights

Escalating Oncology Burden Fueling Demand for Exosome-Based Liquid Biopsy & Therapeutics

Worldwide cancer incidence surpassed 20 million new cases in 2024, intensifying interest in tumor-derived exosomes that carry mutation-specific DNA and oncogenic microRNAs. Liquid-biopsy platforms that isolate circulating vesicles detect EGFR mutations in non-small-cell lung cancer with 92% concordance to tissue biopsy and deliver results in 48 hours, shortening time-to-treatment. Therapeutic development is accelerating; an engineered dendritic-cell exosome achieved a 38% objective response rate in a Phase I melanoma trial completed in 2024. Regulatory clarity arrived when FDA confirmed that exosome therapeutics fall under the 351(a) biologics pathway and must demonstrate potency through functional assays. Companion-diagnostic alliances are expanding, exemplified by the 2025 Qiagen-Bio-Techne pact that bundles isolation kits with next-generation sequencing panels.

Rapid Advances in High-Yield Exosome Isolation Technologies Lowering Cost of Goods

Legacy ultracentrifugation requires 16 hours and yields fewer than 101° particles per milliliter, limiting scalability. New microfluidic chips introduced in 2024 cut isolation time to under 2 hours and recover 1011 particles by combining size-exclusion with immuno-affinity capture. Polymer-based precipitation is faster but co-isolates lipoproteins, forcing downstream filtration that erodes cost advantages. Immuno-affinity capture offers 95% purity yet remains expensive due to antibody consumption and bead regeneration challenges. Point-of-care handheld devices using acoustic trapping isolated exosomes from 50 microliters of whole blood at a per-test cost of USD 8 in a 2025 Indian pilot.

Lack of Standardized Characterization Protocols Undermining Reproducibility

MISEV2023 calls for reporting particle count, size distribution, protein markers, and nucleic-acid content, yet only 28% of 320 studies met all four criteria in 2024. Nanoparticle tracking analysis cannot distinguish lipoproteins, leading to 300% overestimation of exosome counts. Electron microscopy samples fewer than 1,000 vesicles per field, introducing selection bias. FDA now asks developers to prove potency through functional assays, prompting investment in USD 500,000 high-content imaging systems. To aid harmonization, NIST released a 2025 liposome-based reference material for calibrating flow cytometers and ELISAs.

Other drivers and restraints analyzed in the detailed report include:

1. Growing VC & Big-Pharma Investments in Extracellular-Vesicle Drug-Delivery Pipelines
2. Expansion of Companion-Diagnostics Partnerships in Precision Medicine
3. Stringent GMP Compliance Elevating Manufacturing Cost & Complexity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Services & Software is advancing at 39.25% CAGR as laboratories need cloud platforms that transform multi-omic data into clinical insights. Kits & Reagents still delivered 45.56% of revenue in 2025, but low-cost Asian suppliers are squeezing margins. High-priced instruments such as USD 180,000 ultracentrifuges remain essential in GMP suites. Illumina's 2025 launch of an exosome-analysis module trimmed bioinformatics time from 40 hours to 2 hours. ISO 13485 accreditation is now a default requirement, spurring consolidation among quality-assured reagent manufacturers.

Workflow automation tools that shorten sample-to-report cycles underpin the fastest growth. Software vendors bundle analytics with reagents to lock users into ecosystems, while consumables suppliers face price competition. Instruments remain strategic for large pharmaceutical clients because routine GMP release testing still mandates ultracentrifugation, nano-flow cytometry, and transmission electron microscopy.

Although isolation methods generated 55.53% of 2025 revenue, nano-flow cytometry, electron microscopy, and mass spectrometry are climbing at 38.85% CAGR because regulators insist on orthogonal characterization. Ultracentrifugation use is falling as 16-hour runs and rotor maintenance make it unsuited for clinical labs. Microfluidic isolation platforms that recover 1011 particles in 2 hours now dominate new clinical installations. Immuno-affinity capture secures 95% purity but remains expensive, while precipitation kits trade purity for speed.

Downstream analysis differentiates providers; nano-flow cytometry profiles single vesicles, mass spectrometry maps post-translational protein changes linked to drug resistance, and electron microscopy validates morphology albeit at low sample counts. Multi-modal data files feed machine-learning pipelines that clinicians use for treatment decisions, reinforcing demand for integrated analytics suites.

Complete Report Scope:

• By Product
  • Kits & Reagents
  • Instruments
  • Services & Software
• By Workflow
  • Isolation Methods
    • Ultracentrifugation
    • Immuno-affinity Capture
    • Polymer-based Precipitation
    • Microfluidic Isolation
  • Down-stream Analysis
    • Nano-flow Cytometry
    • Electron Microscopy
    • Mass Spectrometry
• By Biomolecule Type
  • Non-coding RNA (miRNA, lncRNA)
  • Proteins & Peptides
  • Lipids
  • mRNA
  • DNA Fragments
• By Source (Cell Type)
  • MSC-derived
  • Tumour-cell-derived
  • Dendritic-cell-derived
  • Platelet-derived
  • Others
• By Application
  • Diagnostics
    • Cancer
    • Neuro-degenerative Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
  • Therapeutics
    • Oncology
    • Regenerative Medicine
    • Drug-Delivery Platforms
• By End-user
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Clinics
  • Diagnostic Centres
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America produced 48.13% of 2025 revenue as FDA guidance spurred new IND filings, NIH disbursed USD 47 million in grants, and venture investment surpassed USD 600 million. Despite market scale, reimbursement lags because CMS assigned only one new-technology payment code in 2025. Canada and Mexico position themselves as trial hubs, aided by accelerated Phase II approvals and fast-track diagnostics for cervical cancer.

Europe ranked second, with Germany, the United Kingdom, and France adopting EMA's 2025 stability requirement that lengthens time-to-market but drives quality. Germany cleared a Phase I Pompe-disease trial for an exosome therapy, and U.K. regulators granted breakthrough status to three diagnostics, reducing review cycles to six months. Southern Europe funds regenerative-medicine consortia, while Switzerland and the Netherlands attract venture capital for vaccine adjuvant platforms.

Asia-Pacific is the fastest-growing region at 39.51% CAGR during 2026-2031. China approved three liquid-biopsy kits for hepatocellular carcinoma in 2025, and Beijing's National Cancer Center rolled out a lung-cancer vesicle test for 10,000 patients, shrinking treatment-decision time from two weeks to three days. Japan's regenerative-medicine statute permits conditional approval based on Phase II data, enabling quick market entry. India emerges as a cost-effective manufacturing base, offering isolation at USD 50 per gram and clearing two handheld tuberculosis analyzers. Australia and South Korea pursue diagnostic leadership, while Singapore and Thailand focus on dengue and liver-cancer screening.

The Middle East & Africa and South America remain smaller but attractive. A 2025 Ugandan field trial demonstrated a 45-minute HIV viral-load test using a USD 50 analyzer, and Brazil fast-tracked a Zika liquid-biopsy platform. Gulf states build precision-medicine hubs, and Argentina cleared a point-of-care analyzer for Chagas disease.

1. Abcam
2. Aegle Therapeutics
3. Aethlon Medical Inc.
4. Aruna Bio
5. Bio-Techne Corp. (Exosome Diagnostics)
6. Biovision
7. Capricor Therapeutics
8. Danaher Corp. (Beckman Coulter)
9. Evox Therapeutics Ltd.
10. ExoCoBio Co. Ltd.
11. ExonanoRNA LLC
12. Fujifilm Holdings Corp.
13. Hologic
14. Illumina
15. JSR Corp. (MBL International)
16. Lonza Group Ltd.
17. Malvern Panalytical Ltd.
18. Miltenyi Biotec
19. Mursla Ltd.
20. NanoSomix Inc.
21. QIAGEN
22. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support